Here's What the Wall Street Thinks About Nuvation Bio Inc. (NUVB) [Yahoo! Finance]
Nuvation Bio Inc. (NUVB) Announces Exclusive Licensing Agreement With Eisai to Expand Global Reach of Taletrectinib [Yahoo! Finance]
A Look At Nuvation Bio (NUVB) Valuation After The Eisai Taletrectinib Licensing Deal [Yahoo! Finance]
Nuvation Bio (NYSE:NUVB) had its price target lowered by analysts at HC Wainwright from $18.00 to $17.00. They now have a "buy" rating on the stock.
Nuvation Bio Reports Preliminary Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook Ahead of 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]